Shulman, M., Choo, T.-H., Ohrtman, K., Pavlicova, M., Rotrosen, J., & Nunes, E. V. (2025). Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial. Drug and Alcohol Dependence, 268, 112550. https://doi.org/10.1016/j.drugalcdep.2025.112550

Zheng, T., Keyes, K., Ji, S., Calderon, A., Wu, E., Doogan, N. J., Villani, J., Chandler, R., Barocas, J. A., Nguyen, T., El-Bassel, N., & Feaster, D. J. (2025). Opioid use disorder prevalence in 57 New York counties from 2017 to 2019: A Bayesian evidence synthesis. Drug and Alcohol Dependence, 267, 112548. https://doi.org/10.1016/j.drugalcdep.2025.112548

Gorfinkel, L. R., Malte, C. A., Fink, D. S., Mannes, Z. L., Wall, M. M., Olfson, M., Livne, O., Keyhani, S., Keyes, K. M., Martins, S. S., Cerdá, M., Gutkind, S., Maynard, C. C., Saxon, A. J., Simpson, T., Gonsalves, G., Lu, H., McDowell, Y., & Hasin, D. S. (2024). Trends in Opioid Use Disorder in the Veterans Health Administration, 2005-2022. JAMA Network Open, 7(12), e2451821. https://doi.org/10.1001/jamanetworkopen.2024.51821

Balise, R. R., Hu, M.-C., Calderon, A. R., Odom, G. J., Brandt, L., Luo, S. X., & Feaster, D. J. (2024). Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. PLOS ONE, 19(11), e0312695. https://doi.org/10.1371/journal.pone.0312695

Presskreischer, R., Mojtabai, R., Mauro, C., Zhang, Z., Wall, M., & Olfson, M. (2025). Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020. Journal of Substance Use and Addiction Treatment, 168, 209568. https://doi.org/10.1016/j.josat.2024.209568

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open, 7(10), e2436612. https://doi.org/10.1001/jamanetworkopen.2024.36612

Williams, A. R., Mauro, C. M., Chiodo, L., Huber, B., Cruz, A., Crystal, S., Samples, H., Nowels, M., Wilson, A., Friedmann, P. D., Remien, R. H., & Olfson, M. (2024). Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug and Alcohol Dependence, 263, 112389. https://doi.org/10.1016/j.drugalcdep.2024.112389

Ruth, A., Ganesh, S. S., Shah, P., Gould, E. E., Ninh, K., Ceasar, R. C., Duncan, D. T., & Bluthenthal, R. N. (2024). Sleep Health among Community-Recruited Opioid-Using People Who Inject Drugs in Los Angeles, CA and Denver, CO. Journal of Urban Health, 101(5), 1058–1067. https://doi.org/10.1007/s11524-024-00922-3

Lim, T. Y., Keyes, K. M., Caulkins, J. P., Stringfellow, E. J., Cerdá, M., & Jalali, M. S. (2024). Improving Estimates of the Prevalence of Opioid Use Disorder in the United States: Revising Keyes et al. Journal of Addiction Medicine, 18(6), 705–710. https://doi.org/10.1097/adm.0000000000001375

Roche, A. I., Young, A., Sabaque, C., Kelpin, S. S., Sinicrope, P., Pham, C., Marsch, L. A., Campbell, A. N. C., Venner, K., Baker-DeKrey, L., Wyatt, T., WhiteHawk, S., Nord, T., Resnicow, K., Young, C., Brown, A., Bart, G., & Patten, C. (2024). Wiidookaage’win: Beta-test of a Facebook group intervention for Native women to support opioid use recovery. Journal of Substance Use and Addiction Treatment, 163, 209396. https://doi.org/10.1016/j.josat.2024.209396

Luba, R., & Comer, S. D. (2024). Opioid vaccine clinical testing: lessons learned. Current Opinion in Psychiatry, 37(4), 264–269. https://doi.org/10.1097/yco.0000000000000945

Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmstrom, P., & Budilovsky-Kelley, N. R. (2024). Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use. JAMA Network Open, 7(6), e2417377. https://doi.org/10.1001/jamanetworkopen.2024.17377

Richardson, M., Hirchak, K., Bajet, K., Brigman, M., Shaffer, R., Keyes, B., Oliver, K. A., Kropp, F., McDonell, M. G., Venner, K. L., & Campbell, A. N. C. (2024). Provider perspectives on the impact of COVID-19 on treatment of substance use and opioid use disorders among American Indian and Alaska Native adults. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1356033

Smith, L. R., Perez-Brumer, A., Nicholls, M., Harris, J., Allen, Q., Padilla, A., Yates, A., Samore, E., Kennedy, R., Kuo, I., Lake, J. E., Denis, C., Goodman-Meza, D., Davidson, P., Shoptaw, S., & El-Bassel, N. (2024). A data-driven approach to implementing the HPTN 094 complex intervention INTEGRA in local communities. Implementation Science, 19(1). https://doi.org/10.1186/s13012-024-01363-x

Meinhofer, A., Chandra, N., Byanova, D., & Keyes, K. M. (2024). Foster Care and Health in Medicaid-Enrolled Children Experiencing Parental Opioid Use Disorder. JAMA Network Open, 7(5), e2410432. https://doi.org/10.1001/jamanetworkopen.2024.10432

Shulman, M., Greiner, M. G., Tafessu, H. M., Opara, O., Ohrtman, K., Potter, K., Hefner, K., Jelstrom, E., Rosenthal, R. N., Wenzel, K., Fishman, M., Rotrosen, J., Ghitza, U. E., Nunes, E. V., & Bisaga, A. (2024). Rapid Initiation of Injection Naltrexone for Opioid Use Disorder. JAMA Network Open, 7(5), e249744. https://doi.org/10.1001/jamanetworkopen.2024.9744

Williams, A. R., Mauro, C. M., Huber, B., Chiodo, L., Crystal, S., Samples, H., & Olfson, M. (2024). Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement. American Journal of Psychiatry, 181(5), 457–459. https://doi.org/10.1176/appi.ajp.20230808

Shulman, M., Provost, S., Ohrtman, K., Novo, P., Meyers-Ohki, S., Van Veldhuisen, P., Oden, N., Otterstatter, M., Bailey, G. L., Liu, D., Rotrosen, J., Nunes, E. V., & Weiss, R. D. (2024). Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials, 142, 107543. https://doi.org/10.1016/j.cct.2024.107543

Brandt, L., Odom, G. J., Hu, M., Castro, C., & Balise, R. R. (2024). Empirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions. Addiction, 119(7), 1289–1300. Portico. https://doi.org/10.1111/add.16494

Glasgow, L., Douglas, C., Sprunger, J. G., Campbell, A. N. C., Chandler, R., Dasgupta, A., Holloway, J., Marks, K. R., Roberts, S. M., Martinez, L. S., Thompson, K., Weiss, R. D., Aldridge, A., Asman, K., Barbosa, C., Blevins, D., Chassler, D., Cogan, L., Fanucchi, L., … El-Bassel, N. (2024). Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial. Drug and Alcohol Dependence, 259, 111286. https://doi.org/10.1016/j.drugalcdep.2024.111286

Eschliman, E. L., Choe, K., DeLucia, A., Addison, E., Jackson, V. W., Murray, S. M., German, D., Genberg, B. L., & Kaufman, M. R. (2024). First-hand accounts of structural stigma toward people who use opioids on Reddit. Social Science & Medicine, 347, 116772. https://doi.org/10.1016/j.socscimed.2024.116772

Xu, K. Y., Gertner, A. K., Greenfield, S. F., Williams, A. R., & Grucza, R. A. (2024). Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims. Addiction Science & Clinical Practice, 19(1). https://doi.org/10.1186/s13722-024-00450-0

Cerdá, M., Hamilton, A. D., Hyder, A., Rutherford, C., Bobashev, G., Epstein, J. M., Hatna, E., Krawczyk, N., El-Bassel, N., Feaster, D. J., & Keyes, K. M. (2024). Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties. Epidemiology, 35(3), 418–429. https://doi.org/10.1097/ede.0000000000001703

Goodman-Meza, D., Shoptaw, S., Hanscom, B., Smith, L. R., Andrew, P., Kuo, I., Lake, J. E., Metzger, D., Morrison, E. A. B., Cummings, M., Fogel, J. M., Richardson, P., Harris, J., Heitner, J., Stansfield, S., & El-Bassel, N. (2024). Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study). Trials, 25(1). https://doi.org/10.1186/s13063-023-07899-5

Wai, J. M., Blevins, D., Hunt, T., Gilbert, L., Campbell, A. N. C., Levin, F. R., El-Bassel, N., & Nunes, E. (2024). An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study. Psychiatric Services, 75(6), 580–588. https://doi.org/10.1176/appi.ps.20230159

McGuirt, A. F., & Brezing, C. A. (2024). Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention. The American Journal of Drug and Alcohol Abuse, 50(2), 132–138. https://doi.org/10.1080/00952990.2023.2292012

O’Grady, M. A., Elkington, K. S., Robson, G., Achebe, I. Y., Williams, A. R., Cohall, A. T., Cohall, R., Christofferson, M., Garcia, A., Ramsey, K. S., Lincourt, P., & Tross, S. (2024). Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators. Substance Abuse Treatment, Prevention, and Policy, 19(1). https://doi.org/10.1186/s13011-024-00593-y

Perez, H. R., Deng, Y., Zhang, C., Groeger, J. L., Glenn, M., Richard, E., Pazmino, A., De La Cruz, A. A., Prinz, M., & Starrels, J. L. (2024). Trajectories of Opioid Misuse and Opioid Use Disorder Among Adults With Chronic Pain and HIV: An Observational Study. Journal of Addiction Medicine, 18(2), 174–179. https://doi.org/10.1097/adm.0000000000001268

Nesoff, E. D., Meisel, Z. F., Saeed, H., & Martins, S. S. (2024). Neighborhood and Individual Disparities in Community-Based Naloxone Access for Opioid Overdose Prevention. Journal of Urban Health, 101(1), 64–74. https://doi.org/10.1007/s11524-023-00821-z

Luo, S. X., Feaster, D. J., Liu, Y., Balise, R. R., Hu, M.-C., Bouzoubaa, L., Odom, G. J., Brandt, L., Pan, Y., Hser, Y.-I., VanVeldhuisen, P., Castillo, F., Calderon, A. R., Rotrosen, J., Saxon, A. J., Weiss, R. D., Wall, M., & Nunes, E. V. (2024). Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry, 81(1), 45. https://doi.org/10.1001/jamapsychiatry.2023.3596

French, R., Lyons, E., Schachter, A., Treston, J. A., Marshall, A., Lattimer, J., Bisaga, A., Behar, E., & Aronowitz, S. V. (2023). “Because of this rotation, this is what I want to do”: Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students. Journal of the American Association of Nurse Practitioners, 35(12), 826–834. https://doi.org/10.1097/jxx.0000000000000949

Castillo, F., Harris, H. M., Lerman, D., Bisaga, A., Nunes, E. V., Zhang, Z., Wall, M., & Comer, S. D. (2023). Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans. Journal of Addiction Medicine, 18(2), 110–114. https://doi.org/10.1097/adm.0000000000001247

Mannes, Z. L., Livne, O., Knox, J., Hasin, D. S., & Kranzler, H. R. (2023). Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample. The American Journal of Drug and Alcohol Abuse, 49(6), 799–808. https://doi.org/10.1080/00952990.2023.2248646

Gopaldas, M., Wenzel, K., Campbell, A. N. C., Jalali, A., Fishman, M., Rotrosen, J., Nunes, E. V., & Murphy, S. M. (2023). Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Psychiatric Services, 74(12), 1227–1233. https://doi.org/10.1176/appi.ps.20220549

Khan, M. R., Hoff, L., Elliott, L., Scheidell, J. D., Pamplin, J. R., Townsend, T. N., Irvine, N. M., & Bennett, A. S. (2023). Racial/ethnic disparities in opioid overdose prevention: comparison of the naloxone care cascade in White, Latinx, and Black people who use opioids in New York City. Harm Reduction Journal, 20(1). https://doi.org/10.1186/s12954-023-00736-7

Perry, A., Wheeler-Martin, K., Terlizzi, K., Krawczyk, N., Jent, V., Hasin, D. S., Neighbors, C., Mannes, Z. L., Doan, L. V., Pamplin II, J. R., Townsend, T. N., Crystal, S., Martins, S. S., & Cerdá, M. (2023). Evaluating chronic pain as a risk factor for COVID-19 complications among New York State Medicaid beneficiaries: a retrospective claims analysis. Pain Medicine, 24(12), 1296–1305. https://doi.org/10.1093/pm/pnad121

Tookes, H. E., Oxner, A., Serota, D. P., Alonso, E., Metsch, L. R., Feaster, D. J., Ucha, J., Suarez, E., Forrest, D. W., McCollister, K., Rodriguez, A., Kolber, M. A., Chueng, T. A., Zayas, S., McCoy, B., Sutherland, K., Archer, C., & Bartholomew, T. S. (2023). Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. Trials, 24(1). https://doi.org/10.1186/s13063-023-07074-w

Frimpong, J. A., Parish, C. L., Feaster, D. J., Gooden, L. K., Nelson, M. C., Matheson, T., Siegel, K., Haynes, L., Linas, B. P., Assoumou, S. A., Tross, S., Kyle, T., Liguori, T. K., Toussaint, O., Annane, D., & Metsch, L. R. (2023). A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs. Trials, 24(1). https://doi.org/10.1186/s13063-023-07602-8

Martinez, S., Garcia-Romeu, A., Perez, F., & Jones, J. D. (2023). Resilience Phenotypes and Psychological Functioning among Individuals with Opioid Use Disorder. Substance Use & Misuse, 59(1), 41–49. https://doi.org/10.1080/10826084.2023.2259450

Mariani, J. J., Basaraba, C., Pavlicova, M., Alschuler, D. M., Brooks, D. J., Mahony, A. L., Brezing, C., Naqvi, N. H., & Levin, F. R. (2023). Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder. The American Journal of Drug and Alcohol Abuse, 49(5), 618–629. https://doi.org/10.1080/00952990.2023.2241981

Mannes, Z. L., Wheeler-Martin, K., Terlizzi, K., Hasin, D. S., Perry, A., Pamplin, J. R., Crystal, S., Cerdá, M., & Martins, S. S. (2023). Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic. Preventive Medicine, 177, 107789. https://doi.org/10.1016/j.ypmed.2023.107789

Tipping, A. D., Nowels, M., Moore, C., Samples, H., Crystal, S., Olfson, M., Williams, A. R., & Heaps-Woodruff, J. (2024). Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study. Journal of Substance Use and Addiction Treatment, 157, 209218. https://doi.org/10.1016/j.josat.2023.209218

Hsu, M., Jung, O. S., Kwan, L. T., Jegede, O., Martin, B., Malhotra, A., & Suzuki, J. (2024). Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. Journal of Substance Use and Addiction Treatment, 157, 209216. https://doi.org/10.1016/j.josat.2023.209216

Hoffman, K. L., Milazzo, F., Williams, N. T., Samples, H., Olfson, M., Diaz, I., Doan, L., Cerda, M., Crystal, S., & Rudolph, K. E. (2023). Independent and joint contributions of physical disability and chronic pain to incident opioid use disorder and opioid overdose among Medicaid patients. Psychological Medicine, 54(7), 1419–1430. https://doi.org/10.1017/s003329172300332x

Young, A., Sinicrope, P., Kelpin, S., Roche, A. I., Sabaque, C., Pham, C., Marsch, L. A., Campbell, A. N. C., Venner, K., Bastian, E., Nord, T., Mason, G., Baker, L., Wyatt, T., Fish, A., Bart, G., & Patten, C. A. (2023). Wiidookaage’Win: A Community-Based Qualitative Approach to Developing a Facebook Group Intervention for Native Women to Support Recovery From Opioid Use. American Journal of Health Promotion, 38(2), 205–218. https://doi.org/10.1177/08901171231205355

Perry, A., Wheeler-Martin, K., Hasin, D. S., Terlizzi, K., Mannes, Z. L., Jent, V., Townsend, T. N., Pamplin, J. R., Crystal, S., Martins, S. S., Cerdá, M., & Krawczyk, N. (2023). Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic. Drug and Alcohol Dependence, 253, 111023. https://doi.org/10.1016/j.drugalcdep.2023.111023

Ware, O. D., Ellis, J. D., Strain, E. C., Antoine, D. G., Martinez, S., & Bergeria, C. L. (2023). Increases in primary opioid use disorder diagnoses co-occurring with anxiety or depressive disorder diagnoses in mental health treatment in the United States, 2015–2019. Drug and Alcohol Dependence, 253, 111022. https://doi.org/10.1016/j.drugalcdep.2023.111022

Mariani, J. J., Dobbins, R. L., Heath, A., Gray, F., & Hassman, H. (2023). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions, 33(1), 8–14. Portico. https://doi.org/10.1111/ajad.13484

Shulman, M., Choo, T.-H., Scodes, J., Pavlicova, M., Novo, P., Campbell, A. N. C., Greiner, M., Lee, J. D., Rotrosen, J., & Nunes, E. V. (2023). Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. Journal of Addiction Medicine, 17(5), 618–620. https://doi.org/10.1097/adm.0000000000001173